Data-driven CRRT

TRUEVUE Analytics is a powerful software that lets you easily look at benchmarks and trends in your CRRT program

Doctor holds tablet and analyzes at data from the PRISMAFLEX System CRRT machine.

If you have a PRISMAFLEX or PRISMAX System, you can use TRUEVUE Analytics to help you:

Improve filter life

Manage lost treatment time

Track dose delivery vs. target

Understand fluid removal rate trends

Featured Presentation

TRUEVUE Analytics: Data-driven CRRT

Michael Olesen, RN, walks through an example report and explains how TRUEVUE Analytics helps you to better analyze your CRRT data, set benchmarks and optimize patient treatment.

Indications and Important Risk Information

The PRISMAFLEX and PRISMAX Systems are intended for:
Continuous Renal Replacement Therapy (CRRT) for patients weighing 20 kilograms or more with acute renal failure and/or fluid overload.

Therapeutic Plasma Exchange (TPE) therapy for patients weighing 20 kilograms or more with diseases where fluid removal of plasma components is indicated.

Rx Only. For safe and proper use of products mentioned herein refer to the appropriate Instructions for Use or Operator's Manual.

PHOXILLUM and PRISMASOL Renal Replacement Solution Indications and Important Risk Information


PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances

Important Risk Information

PHOXILLUM and PRISMASOL replacement solutions are contraindicated in patients with known hypersensitivities to these products.

PHOXILLUM and PRISMASOL solutions can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, calcium, other electrolytes and acid-base balance throughout the procedure.

PHOXILLUM replacement solutions contain hydrogen phosphate, a weak acid that may increase the risk of metabolic acidosis. 

PRISMASOL and PHOXILLUM replacement solutions can affect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Monitor blood glucose levels regularly. 

The following adverse reactions have been identified during post-approval use with these or other similar products and therefore may occur with use of PHOXILLUM or PRISMASOL: Metabolic acidosis, hypotension, acid-based disorders, electrolyte imbalances including calcium ionized increased, hyperphosphatemia, hypophosphatemia, fluid imbalance.

For more information, please see PHOXILLUM and PRISMASOL Solutions full Prescribing Information  or visit


PRISMASATE is a sterile dialysis solution intended for treatment of acute kidney disease (renal failure) using Continuous Renal Replacement Therapies, such as continuous hemodialysis and hemodiafiltation aimed at normalizing the composition of the blood.

Please see PRISMASATE Instructions For Use.

MARS Indications

MARS is indicated for the treatment of drug overdose and poisonings. The only requirement is that the drug or chemical be dialyzable (in unbound form) and bound by charcoal and/or ion exchange resins.

MARS is not indicated for the treatment of chronic liver disease conditions or as a bridge to liver transplant. Safety and efficacy has not been demonstrated for those indications in controlled, randomized clinical trials. The effectiveness of the MARS device in patients that are sedated could not be established in clinical studies and therefore cannot be predicted in sedated patients.